<- Go Home
Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Market Cap
CAD 232.8M
Volume
41.8K
Cash and Equivalents
CAD 9.5M
EBITDA
CAD 12.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CAD 21.4M
Profit Margin
80.78%
52 Week High
CAD 14.09
52 Week Low
CAD 3.80
Dividend
N/A
Price / Book Value
2.35
Price / Earnings
14.38
Price / Tangible Book Value
-82.55
Enterprise Value
CAD 264.0M
Enterprise Value / EBITDA
20.85
Operating Income
CAD 9.9M
Return on Equity
17.98%
Return on Assets
5.05
Cash and Short Term Investments
CAD 9.5M
Debt
CAD 40.8M
Equity
CAD 98.9M
Revenue
CAD 26.5M
Unlevered FCF
-CAD 78.5M
Sector
Pharmaceuticals
Category
N/A